Press Releases

BOSTON, MA – May 5, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that CGuardTM EPS will be featured at the Late-Breaking Trial presentation at the upcoming EuroPCR conference from May 17-20, 2016 in Paris, France. A… Read More

BOSTON, MA – March 31, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced that as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2015, which was filed on March 28,… Read More

BOSTON, MA – March 28, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, today announced its financial and operating results for the fourth quarter and year ended December 31, 2015. In 2015, InspireMD advanced its strategic transition into the… Read More

BOSTON, MA – March 21, 2016 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems (“EPS”), today announced the closing of an underwritten public offering of 1,900,000 shares of its common stock and warrants to purchase up to 950,000 shares of common stock (the “Public Offering”).  The common stock was sold… Read More

BOSTON, MA – March 21, 2016 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems (“EPS”), today announced the closing of its private placement of 1,033,051 shares of its common stock and warrants to purchase up to 516,526 shares of common stock to certain of the Company’s officers and directors (the… Read More

BOSTON, MA – March 16, 2016 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems (“EPS”), today announced the pricing of an underwritten public offering of 1,900,000 shares of its common stock and warrants to purchase up to 950,000 shares of common stock (the “Public Offering”). The common… Read More

BOSTON, MA – March 16, 2016 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems (“EPS”), today announced a private placement (the “Private Placement”) of up to 1,100,000 shares of its common stock and warrants to purchase up to 550,000 shares of common stock to certain of the… Read More

BOSTON, MA – March 15, 2016 – InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR), a leader in embolic protection systems (“EPS”), today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and warrants to purchase common stock. Dawson James Securities, Inc., is serving as the sole… Read More

Enhances Commercial and Development Execution Reduces Operating Cost Structure Strengthens Board of Directors   BOSTON, MA – January 22, 2016 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today plans to align its operations and leadership with focus on… Read More

BOSTON, MA – December 2, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS), neurovascular devices and thrombus management technologies, announced today receipt of a DEKRA medical device certification for the manufacture and commercialization of its CGuardTM delivery catheter, which now incorporates some design enhancements and… Read More